$TCRR

Tcr2 Therapeutics Inc

  • NASDAQ
  • Pharmaceuticals: Major
  • Health Technology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

PRICE

$2.38 ▲1.277%

Last Close

VOLUME

277,344

DAY RANGE

2.3127 - 2.39

52 WEEK

2.1 - 19.85

Join Discuss about TCRR with like-minded investors

profile
@dros #droscrew
recently

Downgrades 1/19: $ALLY $ATVI $BLD $CM $COLD $CSCO $CVLT $DBVT $DHI $DRH $GO $HMPT $IBP $KBH $KOF $LEN $LNT $MIME $MKC $NPCE $PASG $SPIR $TCRR $TFC $TOL $UTZ $ZBH $ZNGA

40 Replies 11 👍 8 🔥

profile
@dros #droscrew
recently

795k $TCRR @ 6.45

84 Replies 12 👍 7 🔥

profile
@dros #droscrew
recently

TCRR a real Gary sort of name

81 Replies 14 👍 14 🔥

profile
@dros #droscrew
recently

695k $TCRR @ 8.94

42 Replies 12 👍 13 🔥

Key Metrics

Market Cap

90.58 M

Beta

1.50

Avg. Volume

503.69 K

Shares Outstanding

38.55 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).

CEO: Garry Menzel

Website:

HQ: 100 Binney St Cambridge, 02142-1096 Massachusetts

Related News